Neurocrine Biosciences traded at $167.40 this Friday November 13th, decreasing $2.00 or 1.18 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences lost 23.17 percent. Over the last 12 months, its price rose by 15.56 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 163.63 by the end of this quarter and at 152.83 in one year, according to Trading Economics global macro models projections and analysts expectations.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.